Beth Christian

Beth Christian, MD


Make an Appointment


Overall Patient Satisfaction Rating

4.9 out of 5




I am a hematologist and oncologist who specializes in treating patients with Hodgkin’s and non-Hodgkin’s lymphoma. I am currently an assistant professor in the Department of Internal Medicine, Division of Hematology. I studied biomedical engineering at Tulane University before receiving my medical training at The Ohio State University. I was rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016 and 2017.

As a researcher, I’m passionate about finding novel therapies for cancer patients. Currently, my research is focused on designing and leading clinical trials. I’m proud to be the principle investigator in several trials that could help advance our fight against lymphoma. I’m inspired by the dual focus on both cutting-edge research and quality patient care that I find at OSUCCC – James. It’s what makes The James such a unique place.

Medical education is also very important to me. I am dedicated to teaching and mentoring medical students who will be future leaders in the fight against lymphoma and other cancers.

Education and Background


Ohio State University College of Medicine

Columbus, OH


Ohio State University Wexner Medical Center

Columbus, OH



Ohio State University Wexner Medical Center

Columbus, OH

Board Certifications

American Board of Internal Medicine

American Board of Internal Medicine (Subspecialty: Hematology)

American Board of Internal Medicine (Subspecialty: Medicine Oncology)

Academic Department

Department of Internal Medicine

Division of Hematology

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 12/20/2018, Dr. Christian has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.



Patient Satisfaction Review

The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our Patient Satisfaction Survey page

The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.

Overall Ratings (out of 106 reviews)
4.9 out of 5
Kept you informed about your condition and treatment

4.9/ 5

Amount of time spent with you

4.9/ 5

Concern for your questions and issues

4.9/ 5

Skill and knowledge

4.9/ 5

Overall quality of care

4.9/ 5

Patient Comments (4 total comments)

Reviewed: 4/14/2019

we just adore Dr. Christian and her staff!

Reviewed: 3/25/2019

Dr Christian is everything a doctor should be and more. She is completely professional, direct, compassionate and thorough.

Reviewed: 3/4/2019

Dr. Christian saved my life! I will do anything she tells me to ensure that my cancer never returns.

Reviewed: 2/12/2019

Our doctor is awesome. Nevee hurries is and answers all of our questions. She is very knowledgeable.


Resistance mechanism for ibrutinib in marginal zone lymphoma.

Epperla N, Shana'ah AY, Jones D, Christian BA, Ayyappan S, Maddocks K, Woyach JA

Blood Adv 3


A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58


Clinical Trials | Lead



Back to Find a Doctor Search

Make an Appointment


Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator


Please enter a keyword (i.e. Name, Location) or choose a Cancer Type